Paul R. Kirchgraber - Mar 27, 2022 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Stock symbol
LH
Transactions as of
Mar 27, 2022
Transactions value $
-$455,540
Form type
4
Date filed
3/29/2022, 12:04 PM
Previous filing
Feb 15, 2022
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Award $0 +3.71K +37.61% $0.00 13.6K Mar 27, 2022 Direct F1
transaction LH Common Stock Tax liability -$456K -1.65K -12.15% $276.42 11.9K Mar 28, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.
F2 Stock withholding to satisfy tax withholding obligations.